United States Patent 4,521,405: Claims Analysis and U.S. Patent Landscape (Multiple Sclerosis, Histamine, Inactivated/Attenuated Measles Virus)
What does US 4,521,405 claim, in technical and legal terms?
US 4,521,405 claims a treatment method and a corresponding composition for alleviating symptoms of multiple sclerosis (MS) (claim 1) and, more broadly, a “non-anaphylactic disease state” in which the humoral and/or cell-mediated immune response participates in pathology (claim 8). The core invention is the combination of histamine with inactivated, attenuated measles virus (or an immunologically active fraction thereof) administered to a patient.
Claim set (scope and mandatory elements)
Method claims
- Claim 1 (MS method): Administer an “effective amount” of a composition comprising:
- a mixture of histamine, and
- inactivated, attenuated measles virus or an immunologically active fraction thereof,
to alleviate MS symptoms.
- Claim 2 (virus definition): Measles virus is an inactivated, attenuated vaccine strain.
- Claim 3 (dose ratio limit): Unit dosage contains an inactivated/attenuated measles virus amount of:
- from 2 × 10^-3 to 4 × 10^-4 times the “prescribed vaccination dose” of that measles vaccine strain.
- Claim 4 (histamine form): Histamine administered as a water-soluble histamine salt.
- Claim 5 (histamine mass range): Unit dosage contains histamine phosphate from:
- 8.8 × 10^-6 mg to 5.5 × 10^-3 mg.
- Claim 6 (route): Composition administered parenterally.
- Claim 7 (route variants): Administered subcutaneously or sublingually.
Composition claims
- Claim 8 (broad “non-anaphylactic disease state”): Composition for alleviating symptoms of a disease state where humoral and/or cell-mediated immunity participates in pathology, comprising:
- an “effective amount” of histamine + inactivated, attenuated measles virus mixture.
- Claim 9 (virus definition in composition): Measles virus is an effective amount of an inactivated, attenuated vaccine strain.
What is the claim’s infringement “center of gravity”?
Across claims 1 and 8, the claim’s mandatory combination is:
1) histamine; and
2) inactivated, attenuated measles virus (or immunologically active fraction);
3) used at an “effective amount” to alleviate symptoms; and
4) in the method claims, applied to an MS patient population; in composition claim 8, to a class of immune-participatory diseases (non-anaphylactic).
Secondary constraints (in dependent claims) narrow implementation:
- measles must be an inactivated attenuated vaccine strain (claims 2 and 9);
- specified dosage relationships (claim 3) and histamine phosphate mass range (claim 5);
- specified routes (claims 6 and 7);
- histamine must be in a water-soluble salt (claim 4).
How strong are the claims on novelty and obviousness?
US 4,521,405 reads as a classic combination patent: it does not claim a new measles virus per se or a new histamine composition per se. It claims a therapeutic pairing plus parameterized dosing and routes. That structure usually concentrates patentability on:
- whether histamine use in immune-mediated diseases was known,
- whether measles virus immunotherapy or vaccine-derived immunological effects were known, and
- whether prior art taught that combining histamine with inactivated/attenuated measles virus would alleviate MS symptoms or immune-mediated pathology.
Key claim risks (by element)
| Claim element |
What must be proved as “present in prior art” to challenge novelty |
Usual patentability pressure |
| Histamine (or histamine salts) used in immune/autoimmune conditions |
Prior disclosures of histamine modulation of immune responses in inflammatory/autoimmune disease |
Often easier to find as background therapeutic rationale |
| Inactivated/attenuated measles virus as an immunological therapeutic agent |
Prior vaccination/immunization rationale using measles virus derivatives for immune modulation (even if not MS-specific) |
Could be shown through vaccine immunology teachings |
| Combination: histamine + measles virus (inactivated, attenuated) |
Prior art that explicitly combines histamine with viral immunogens or uses one to potentiate immune effects of the other |
Combination obviousness is the most likely attack line |
| MS symptom alleviation using this combination |
Prior MS treatment using either component alone, or viral/inactivated immunotherapies, plus immune modulation rationale |
MS-specific teaching is often the hardest element to find in one reference, but can be assembled via KSR-style combinations |
| Immunologically active fraction of measles virus |
Prior art defining that inactivated viral preparations or fractions retain immunologic activity |
Usually supported by general vaccine fraction teachings |
| Dosing constraints (virus dose fraction; histamine phosphate microgram range) |
Prior art with dose ranges, or teaching that “very low” histamine doses used with vaccine agents produce immunomodulatory effects |
If dose ranges overlap, claims become vulnerable to anticipation or obviousness |
The most vulnerable claim features
1) “Mixture of histamine and inactivated, attenuated measles virus” as the universal core in both method and composition claims. If prior art already taught histamine for immune modulation and separately taught measles vaccine virus for immune effects, then the combination becomes a predictable therapeutic rationale.
2) “Effective amount” language in claims 1 and 8 leaves breadth and creates a logical bridge for obviousness arguments: prior art does not need identical outcomes, only expectation of therapeutic effect in immune-participatory disease states.
3) Immunologically active fraction (claim 1) increases susceptibility to obviousness and non-limiting interpretation because fractions of inactivated viruses are common in vaccine immunology.
Where dependent claims can add real narrowing
Dependent claims 3, 5, 6, and 7 specify:
- a fraction of prescribed vaccination dose for the measles virus (a defined dosing relationship), and
- a tight histamine phosphate microgram-to-milligram mass range, and
- parenteral administration including subcutaneous or sublingual.
These limits can be meaningful for validity if the prior art does not disclose overlapping dosing ranges or routes.
What is the claim scope in practice (coverage map)?
Core coverage (claims 1 and 8)
To infringe claim 1 or 8, a product or regimen must include:
- histamine (or histamine salt in workable embodiments),
- measles virus that is both inactivated and attenuated (or an immunologically active fraction),
- administration or formulation sufficient to alleviate symptoms,
- with claim 1 additionally requiring MS patient treatment.
Narrower implementation coverage (claims 2-7 and 9)
Practically, the strongest “implementation” constraints are:
- measles virus must be an inactivated attenuated vaccine strain;
- unit dosage virus amount is a specific fraction of the prescribed vaccination dose (claim 3);
- histamine phosphate mass range is 8.8 × 10^-6 mg to 5.5 × 10^-3 mg per unit dosage (claim 5);
- route is parenteral, including subcutaneous or sublingual (claims 6 and 7);
- histamine is a water soluble salt (claim 4).
What is the U.S. patent landscape likely to look like around this concept?
Without case-file or prosecution history, the landscape analysis focuses on likely categories of patents and how they intersect with the claim’s unique combination.
Landscape lanes that typically collide with US 4,521,405
1) MS immunomodulation patents (U.S.)
- Methods combining immune modulation with cytokines, immune cell targeting, or non-specific immune stimulants.
- Overlap risk rises if any prior MS regimen included viral immunogens or vaccine-based immunostimulation.
2) Viral immunotherapy and vaccine-adjacent patents
- Patents about using inactivated/attenuated viruses or viral antigens as immunotherapeutics.
- If prior art includes measles or measles-derived antigen as an immunomodulator, that narrows novelty.
3) Histamine and histamine receptor modulation patents
- Use of histamine, histamine salts, or histamine pathway modulation for immune or inflammatory disease.
- A prior disclosure that histamine improves immune regulation would support obviousness.
4) Combination immunotherapy patents
- Patents pairing an immune mediator (small molecule or cytokine) with vaccine-derived antigens or immunostimulants.
- Even if not measles-specific, a general combination pattern can be used to attack claim 1 through obviousness.
Critical reading: what would block US 4,521,405 in prior art?
A strong prior-art blocker would be:
- a U.S. disclosure that uses histamine together with measles virus preparations (even if “inactivated” wording differs), in an immune-mediated disease context, or
- an MS regimen using a measles vaccine strain plus immune modulators, where histamine is among the contemplated modulators.
Critical reading: what likely keeps parts of the claims alive?
Even if histamine and measles viral immunology exist in the literature separately, the claims can survive if the combination with specified dosing relationships and routes is not taught and is not obvious based on available teachings at the time.
How should investors and R&D teams interpret claim enforceability?
Enforceability bottlenecks
- Broad “effective amount” + mixture language is litigation-sensitive: infringement analysis may turn on dosing definitions (unit dosage vs. “prescribed vaccination dose”) and on whether the measles preparation qualifies as both inactivated and attenuated.
- Dose fraction claim 3 and histamine microgram range in claim 5 create technical enforcement leverage, but also create practical development constraints. If a competitor’s dosing falls outside these ranges, infringement may be avoided even if the therapeutic concept overlaps.
Development strategy implications
- A product that uses histamine and measles virus but differs in histamine salt, dosing mass, or virus dose fraction may avoid some dependent claims.
- If a competitor uses a measles immunogen but not an inactivated attenuated vaccine strain, claims 2 and 9 become a key potential non-infringement argument.
- Route changes can matter: claims 6 and 7 require parenteral, with subcutaneous or sublingual.
Key legal and technical observations specific to the claim language
1) “Mixture”: The claims read on a co-formulation or co-administration regime that qualifies as a composition “comprising a mixture” (claim 1 and 8). Separate dosing schedules could still be argued as a “mixture” depending on claim construction, but the cleanest infringement fact pattern is a combined regimen/formulation.
2) “Inactivated, attenuated”: This is a dual requirement. Many viral immunotherapies are inactivated but not attenuated (or vice versa). The patent demands both characteristics.
3) “Immunologically active fraction”: This captures partial viral components that retain immunological activity. Competitors attempting to design around by using only antigenic components still risk capture if those components qualify as immunologically active fractions of an inactivated attenuated measles virus preparation.
4) Disease scope in claim 8: The “non-anaphylactic disease state” language is broad but not unlimited. The claim is tied to immune participation in pathology and excludes anaphylactic disease states. This may reduce some prior art overlap if prior art focuses on anaphylaxis.
Key Takeaways
- US 4,521,405 claims a combination therapy: histamine plus inactivated, attenuated measles virus (or an immunologically active fraction), used to alleviate MS symptoms (claim 1) and more broadly immune-participatory, non-anaphylactic disease states (claim 8).
- The strongest enforceability lever is the combination itself; the strongest potential validity defense for the patent holder is the specific dosing constraints and administration routes in dependent claims (notably claim 3 and claim 5, plus claims 6 and 7).
- The most probable invalidity attack line in the U.S. is combination obviousness, built from prior art that separately disclosed: (a) histamine-related immune modulation and (b) measles vaccine-derived immunological activity, then arguing a predictable combination for immune-mediated disease outcomes.
- Practically, claim 3 (virus dose as a fraction of a prescribed vaccination dose) and claim 5 (histamine phosphate microgram-to-milligram range per unit dosage) provide concrete technical gates that can affect both infringement and design-around feasibility.
FAQs
1) What disease does US 4,521,405 directly cover?
Multiple sclerosis symptoms via claim 1; claim 8 extends to “non-anaphylactic” immune-participatory disease states, but MS is the most explicit target.
2) Does the patent require live measles virus?
No. It requires inactivated, attenuated measles virus or an immunologically active fraction.
3) What dosing specificity exists in the claims?
Claim 3 specifies a virus amount as a fraction of the “prescribed vaccination dose.” Claim 5 specifies histamine phosphate mass per unit dosage from 8.8 × 10^-6 mg to 5.5 × 10^-3 mg.
4) Are administration routes limited?
Yes. Dependent claims require parenteral administration (claim 6) and specify subcutaneous or sublingual (claim 7).
5) What would most likely differentiate a competing regimen from infringement?
Departing from the specified measles virus type (not an inactivated attenuated vaccine strain), avoiding the histamine salt/form and dosing ranges, or using a non-parenteral route.
References
[1] United States Patent 4,521,405. “Method for alleviating the symptoms of multiple sclerosis disease state” (claims as provided).
